Triple

T10837769
Position Surface form Disambiguated ID Type / Status
Subject Bruton tyrosine kinase E255805 entity
Predicate isTherapeuticTargetOf P37016 FINISHED
Object zanubrutinib
Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
 E890926 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: zanubrutinib | Statement: [Bruton tyrosine kinase, isTherapeuticTargetOf, zanubrutinib]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: zanubrutinib
Context triple: [Bruton tyrosine kinase, isTherapeuticTargetOf, zanubrutinib]
  • A. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • B. acalabrutinib
    Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • C. Venclexta
    Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: zanubrutinib
Triple: [Bruton tyrosine kinase, isTherapeuticTargetOf, zanubrutinib]
Generated description
Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: zanubrutinib
Target entity description: Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • A. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • B. acalabrutinib
    Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • C. Venclexta
    Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa81a5d08190aa86689061d1ddd2 completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d747002b3081908726901ee83d8f38 completed April 9, 2026, 6:28 a.m.
NED1 Entity disambiguation (via context triple) batch_69dff7c739708190b0d58fc2d6392c6c completed April 15, 2026, 8:40 p.m.
NEDg Description generation batch_69e0026e7900819087327db5f625169c completed April 15, 2026, 9:26 p.m.
NED2 Entity disambiguation (via description) batch_69e0057a7704819096becb74dc261883 completed April 15, 2026, 9:39 p.m.
Created at: April 8, 2026, 9:19 p.m.